This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
multiple-myeloma
Multiple Myeloma
Plasma cell malignancy driven by CCND1 translocations (t(11;14)), RAS-MAPK mutations, and MYC. Bortezomib, lenalidomide, and daratumumab transformed outcomes; venetoclax is active in t(11;14) MM; BCMA-targeted CAR-T (cilta-cel, ide-cel) and bispecifics (teclistamab) are approved.
Entry Metadata
| Field | Value |
|---|---|
| ID | multiple-myeloma |
| Name | Multiple Myeloma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(12):1685-1717. · PubMed 33285519
- Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505. · PubMed 35661166
- San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. · PubMed 37285856